CD8A and infection: Subsequent T-cell vaccine strategies in the 2000s used viral vectors, such as adenovirus type 5, to induce robust CD8+ T-cell immunity; however, the STEP trial from 2004 to 2007 failed to prevent infection or reduce viral loads and even showed a higher infection rate in certain subgroups of vaccine recipients [3].